underlying 'effector' transcript driving these effects has not been established (3, 4) . Rodent studies have linked to glucose homeostasis, pointing to the gene as a 31 plausible candidate effector transcript at the locus. In a β2cell specific knockout 32 mouse, deficiency was found to increase β2cell proliferation and conferred resistance 33 to chemically2induced diabetes (9) . Overexpression, in contrast, reduced β2cell proliferation 34 in both young and old mice. This is consistent with the effect of 2loss, which has been 35 shown to result in a reduced number of pancreatic β2cells and insulin2deficient diabetes (10) .
36
More recent mouse studies have also established a role for and in hepatic 37 glucose production (HGP), demonstrating cell2cycle independent effects on gluconeogenesis 38 under fasted and fed conditions (11, 12 
133
To confirm these findings, we performed IVGTTs on eight cases and eight controls knockdown in the human β2cell line, EndoC2bH1-Silencing of (5 ) ) and non2targeting sequence () ) ) was performed using pools of siRNA (10 nM), and knockdown confirmed both at the mRNA level ( 
Matsuda ISI Insulin Sensitivity 10 000 * √(glucose 0 * insulin 0 * glucose mean-OGTT * insulin mean-OGTT ) chronically elevated insulin levels due to β-cell hypersecretion drives a progressive decrease in insulin receptors and insulin signalling through homologous desensitization (8) . In this case, the primary effect of CDKN2A loss is on the pancreatic beta-cell, but the mechanism ultimately manifests as impaired insulin sensitivity and reduced insulin clearance. As discussed in the main text, it is likely that a combination of the two models contributes to both beta-cell hypersecretion and primary insulin resistance. 
